Thanks to companies like Seattle Genetics, the Puget Sound region in Washington state is drawing more attention as a cancer research hub. A fact highlighted by a recent visit by vice president Joe Biden.
Under the guidance of CEO Clay Siegall, Seattle Genetics has some ambitious plans for expansion. Currently, the company has a drug, Adcetris, in advanced clinical trial, also known as Phase 3. The drug is being used as a “frontline” treatment for patients diagnosed with Hodgkin lymphoma.
According to Siegall, the results of that trial will have “the biggest impact” on the company out of all the trials being conducted this year. In 2015 the drug had $226 million in sales in the United Staes and Canada. The company predicts that the drug will sell between $255 and $275 million in 2016.
Along with Adcetris, the company has 12 other drugs they are developing at the moment. All drugs are designed to battle different forms of cancer, from leukemia to breast and bladder cancer.
Siegall also plans to expand Seattle Genetics’ workforce. Currently, the company has just over 800 employees. Siegall plans to add another 100 employees in the U.S. and another 20 to the Switzerland office. Going forward, he said his offices have room for an additional 350 employees. It remains to be seen how fast he wants to add those additional employees.
Dr. Siegall co-founded Seattle Genetics in 1998. Before that, he worked for the Bristol-Myer Squibb Pharmaceutical Research Institute. He received a B.S. in Zoology from the University of Maryland he then went on to George Washington University where he earned a Ph.D. in Genetics.